IRLAB Therapeutics AB (publ) Cash Flow Conversion Efficiency

Latest as of December 2025: -0.787x

IRLAB Therapeutics AB (publ) cash flow conversion efficiency. Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has a cash flow conversion efficiency ratio of -0.787x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-24.18 Million ≈ $-2.60 Million USD) by net assets (Skr30.72 Million ≈ $3.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of IRLAB Therapeutics AB (publ) (2014–2025)

Cash flow conversion efficiency of IRLAB Therapeutics AB (publ) from 2014 to 2025. This chart illustrates how IRLAB Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View IRLAB-A stock price and chart for real-time trading data and today's change.

IRLAB Therapeutics AB (publ) Cash Flow Conversion Ratio Explained

IRLAB Therapeutics AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

IRLAB Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their cash flow conversion efficiency. Also see market cap of IRLAB Therapeutics AB (publ) for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Gediz Ambalaj Sanayi ve Ticaret AS IS:GEDZA	0.012x
17 Education Technology Group Inc NASDAQ:YQ	-1.269x
CHARBONE HYDROGEN CORP. F:K47	0.315x
Mirae ING Co Ltd KO:007120	0.039x
Falcon Power Co Ltd TW:1516	0.032x
Cubic Korea Inc KQ:021650	-0.024x
Studio Mir Co. Ltd. KQ:408900	-0.036x
Arco Vara AS F:AV1	-0.098x

Annual Cash Flow Conversion Efficiency for IRLAB Therapeutics AB (publ) (2014–2025)

The table below shows the annual cash flow conversion efficiency of IRLAB Therapeutics AB (publ) from 2014 to 2025. Review IRLAB-A free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr30.72 Million ≈ $3.31 Million	Skr-55.22 Million ≈ $-5.94 Million	-1.798x	+10.56%
2024-12-31	Skr32.63 Million ≈ $3.51 Million	Skr-65.59 Million ≈ $-7.06 Million	-2.010x	-41.14%
2023-12-31	Skr115.76 Million ≈ $12.46 Million	Skr-164.85 Million ≈ $-17.74 Million	-1.424x	-190.40%
2022-12-31	Skr290.83 Million ≈ $31.30 Million	Skr-142.61 Million ≈ $-15.35 Million	-0.490x	-252.28%
2021-12-31	Skr399.48 Million ≈ $42.99 Million	Skr128.64 Million ≈ $13.84 Million	0.322x	+225.57%
2020-12-31	Skr347.88 Million ≈ $37.44 Million	Skr-89.21 Million ≈ $-9.60 Million	-0.256x	+48.87%
2019-12-31	Skr181.83 Million ≈ $19.57 Million	Skr-91.20 Million ≈ $-9.81 Million	-0.502x	-50.55%
2018-12-31	Skr212.48 Million ≈ $22.87 Million	Skr-70.79 Million ≈ $-7.62 Million	-0.333x	+10.56%
2017-12-31	Skr155.00 Million ≈ $16.68 Million	Skr-57.74 Million ≈ $-6.21 Million	-0.373x	+5.19%
2016-12-31	Skr103.89 Million ≈ $11.18 Million	Skr-40.82 Million ≈ $-4.39 Million	-0.393x	-30.74%
2015-12-31	Skr92.03 Million ≈ $9.90 Million	Skr-27.66 Million ≈ $-2.98 Million	-0.301x	-141.45%
2014-12-31	Skr88.57 Million ≈ $9.53 Million	Skr-11.02 Million ≈ $-1.19 Million	-0.124x	--

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$18.49 Million

Skr171.84 Million SEK

Market Cap Rank

#25199 Global

#501 in Sweden

Share Price

Skr2.03

Change (1 day)

-2.64%

52-Week Range

Skr1.20 - Skr2.40

All Time High

Skr104.95